Top Page
Aspira Women's Health
(OTC:AWHL)
Aspira Women's Health (AWHL) vs. SPDR S&P 500 ETF (SPY)
Aspira Women's Health Business Overview & Revenue Model
Aspira Women's Health Earnings Call Summary
Aspira Women's Health Financial Statement Overview
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Aspira Women's Health Technical Analysis
Aspira Women's Health Risk Analysis
Aspira Women's Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $33.45M | -17.08 | -14.76% | ― | 27.05% | 55.03% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $8.61M | ― | ― | ― | ― | ― | |
| ― | $20.89M | -1.03 | ― | ― | 4.10% | 67.32% | |
| ― | $51.23M | ― | ― | ― | 35.10% | 39.15% | |
| ― | $53.84M | -1.20 | -219.68% | ― | 25.70% | 39.25% | |
| ― | $17.91M | -0.34 | ― | ― | -4.40% | -6.31% |
Aspira Women's Health Corporate Events
On October 14, 2025, Aspira Women’s Health Inc. transitioned from the OTCQB® Venture Market to the more prestigious OTCQX market, trading under the symbol ‘AWHL.’ This upgrade signifies a strategic advancement for the company, potentially enhancing its visibility and credibility within the financial markets.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
On March 5, 2025, Aspira Women’s Health Inc. entered into a securities purchase agreement with existing accredited shareholders for a private placement of $1,370,000 in Senior Secured Convertible Promissory Notes, which have since been converted into units of common stock and warrants. On September 19, 2025, the company amended the agreement to exclude certain securities from ‘Exempt Issuance,’ required filing a registration statement, and allowed purchasers to appoint directors to the board. The amendment also adjusted terms of the warrants, including a fixed exercise price and extended term.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
On September 16, 2025, Aspira Women’s Health Inc. entered into securities purchase agreements with investors, resulting in a private placement of common stock and warrants, raising approximately $2.95 million. The company plans to use these funds for working capital and general corporate purposes. This financial move, along with an additional $112,500 from warrant exercises, provides Aspira with a total equity capital infusion of $3.06 million. This capital will support Aspira’s ongoing commercial activities and growth plans, as the company focuses on executing its strategic goals and expanding its innovative product pipeline in women’s health diagnostics.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
On September 2, 2025, Aspira Women’s Health appointed Brian Hungerford as its Chief Financial Officer and Principal Accounting Officer, replacing Julie Carrillo. Hungerford, with over 20 years of experience, previously served as CFO for Kiromic Biopharma, Inc. His compensation package includes a $300,000 annual salary, a potential 35% cash bonus, and stock options. The Consulting Agreement outlines terms for salary continuation and stock option vesting in the event of termination without cause or following a change of control.
The most recent analyst rating on (AWHL) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.
Aspira Women’s Health Inc. is a Delaware-based company focused on developing and commercializing diagnostic tests for gynecologic diseases, primarily operating in the healthcare sector. The company is known for its innovative diagnostic solutions, including the Ova1Plus and OvaWatch tests, which are part of their OvaSuite product line.